drug
valemetostat
Phase 2updated 6mo agoby Daiichi Sankyo Co Ltd
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying valemetostat
- —Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
- phase1A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- phase2A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
- phase1A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
- phase1Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- phase1A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- phase2Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
- phase2A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that